Sökning: WFRF:(Koltowska Häggström Maria 1957 ) >
The cost-effectiven...
The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in Sweden
-
- Bolin, Kristian (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för nationalekonomi med statistik,Department of Economics,Department of Economics, Centre for Health Economics, University of Gothenburg, Sweden
-
- Sandin, R. (författare)
- Pfizer AB, Sollentuna, Stockholm, Sweden
-
- Koltowska-Häggström, Maria, 1957- (författare)
- Pfizer, Endocrine Care, Pfizer Inc, Sollentuna, Sweden,Barnendokrinologisk forskning/Gustafsson
-
visa fler...
-
- Loftus, J. (författare)
- Pfizer Ltd, Walton Oaks, UK
-
- Prütz, C. (författare)
- Pfizer AB, Sollentuna, Stockholm, Sweden
-
- Jonsson, Björn, 1939- (författare)
- Uppsala universitet,Institutionen för kvinnors och barns hälsa,Barnendokrinologisk forskning/Gustafsson
-
visa färre...
-
(creator_code:org_t)
- Springer Science and Business Media LLC, 2013
- 2013
- Engelska.
-
Ingår i: Cost Effectiveness and Resource Allocation. - : Springer Science and Business Media LLC. - 1478-7547. ; 11:1
- Relaterad länk:
-
https://resource-all...
-
visa fler...
-
https://doi.org/10.1...
-
https://uu.diva-port... (primary) (Raw object)
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: To evaluate the cost-effectiveness of growth hormone (GH) treatment (Genotropin®) compared with no GH treatment in adults with GH deficiency in a Swedish societal setting.Methods: A Markov-type cost-utility simulation model was constructed and used to simulate, for men and women, morbidity and mortality for GH-treated and -untreated individuals over a 20-year period. The calculations were performed using current available prices concerning morbidity-related healthcare costs and costs for Genotropin®. All costs and treatment effects were discounted at 3%. Costs were expressed in Euro (1€ = 9.03 SEK). GH-treated Swedish patients (n = 434) were identified from the KIMS database (Pfizer International Metabolic Database) and untreated patients (n = 2135) from the Swedish Cancer Registry and the Hospital Discharge Registry.Results: The results are reported as incremental cost per quality-adjusted life year (QALY) gained, including both direct and indirect costs for GH-treated versus untreated patients. The weighted sum of all subgroup incremental cost per QALY was €15,975 and €20,241 for men and women, respectively. Including indirect cost resulted in lower cost per QALY gained: €11,173 and €10,753 for men and women, respectively. Key drivers of the results were improvement in quality of life, increased survival, and intervention cost.Conclusions: The incremental cost per QALY gained is moderate when compared with informal thresholds applied in Sweden. The simulations suggest that GH-treatment is cost-effective for both men and women at the €55,371 (SEK 500,000 - the informal Swedish cost-effectiveness threshold) per QALY threshold. © 2013 Bolin et al.; licensee BioMed Central Ltd.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)
Nyckelord
- Adults
- Cost effectiveness
- Growth hormone
- QALY
- adult
- aged
- article
- cerebrovascular accident
- cost effectiveness analysis
- cost of illness
- cost utility analysis
- Cushing disease
- economic evaluation
- female
- growth hormone deficiency
- health care cost
- hidden Markov model
- human
- hypophysis adenoma
- ischemic heart disease
- major clinical study
- male
- morbidity
- mortality
- nonfunctioning pituitary adenoma
- quality adjusted life year
- quality of life
- simulation
- substitution therapy
- Sweden
- therapy effect
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas